Checkpoint Inhibitors for Cancer and Autoimmunity
Autoimmunity After Checkpoint Blockade
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 600 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Other
This trial is looking for people with cancer who are receiving treatment with checkpoint inhibitors. Participants will help researchers understand why some patients develop immune-related side effects from this treatment.
You may be able to join if
- I have been diagnosed with cancer
- I have a prescription for a checkpoint inhibitor
You may not be able to join if
- I am not willing or able to give consent
- I am under the age of 18
- I have a history of transplant
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your EligibilityThe purpose of this study is to better understand how the treatment of cancer with immune checkpoint inhibitors (ICI) leads to the development of autoimmunity. Specifically, we wish to understand the genetics and immune system features that cause a subset of cancer patients treated with checkpoint inhibitor therapy to develop an immune-related adverse event (irAE).
Loading trial locations…